Ibrutinib for Mantle Cell Lymphoma: BTK Mechanism, Response Is Not Cure, Post-Resistance Options

　　1.Why It Works in MCL

　　Mantle cell lymphoma is a B-cell non-Hodgkin lymphoma in which some clones depend on B-cell receptor signaling for survival and proliferation.

　　Ibrutinib is a Bruton tyrosine kinase inhibitor.It covalently binds BTK,blocks phosphorylation and downstream signaling,and reduces malignant B-cell survival,migration,and adhesion.

　　Eligibility:

　　adult;

　　mantle cell lymphoma;

　　at least one prior therapy;

　　prescribed by hematology/oncology.

　　It is not a universal first-line option for every MCL case.

　　2.Response≠Cure

　　Ibrutinib may shrink nodes and control symptoms,but remission does not mean all tumor cells are eradicated.

　　Some patients progress later through clonal evolution,bypass signaling,or resistance mechanisms.TP53 abnormality,high proliferation index,and complex karyotype affect duration.

　　Judgment needs more than"tumor got smaller":

　　partial vs complete response;

　　duration of control;

　　fever,night sweats,weight loss;

　　imaging and biopsy when progression suspected.

　　Goal is often durable control,not guaranteed cure;dose changes are clinician-led.

　　3.Monitoring During Therapy

　　Bleeding

　　Platelet-function effects cause bruising,epistaxis,gum bleeding;serious GI or intracranial bleeding possible.Combining aspirin,clopidogrel,warfarin,DOACs,NSAIDs raises risk.

　　Infection

　　Upper respiratory infection,pneumonia,herpes zoster,occasional opportunistic infection.Screen HBV before start;assess TB and immune status when indicated.

　　Cytopenias

　　Neutropenia,thrombocytopenia,anemia—CBC regularly.

　　Cardiac

　　Atrial fibrillation/flutter,hypertension,worsening heart failure;report palpitations,chest tightness,dyspnea,edema.

　　Interactions

　　CYP3A4 substrate:

　　avoid strong CYP3A inhibitors raising levels;

　　avoid strong inducers lowering efficacy;

　　no grapefruit/Seville orange.

　　Swallow capsules whole once daily;surgery hold decided by prescriber.

　　4.If Ineffective or Progressive

　　Not simply"switch to another BTK inhibitor":

　　second-generation covalent BTK inhibitors:acalabrutinib,zanubrutinib;

　　non-covalent reversible BTK inhibitor:pirtobrutinib for some C481-resistance settings;

　　combination:ibrutinib+venetoclax within specialist framework;

　　bispecific CD20×CD3;

　　CAR-T:relevant after cBTK exposure in R/R MCL;

　　clinical trials:BTK degraders,ROR1 ADC;

　　transplant:individualized for fit,chemo-sensitive,high-risk cases.

　　Choice depends on prior lines,BTK exposure,remission duration,TP53 status,fitness,and access.